

# ANZTCT Registry

## Annual Data Summary 2022

### Contents

<b>Introduction .....</b>	<b>1</b>
<b>Registry data 1992-2022 .....</b>	<b>2</b>
Transplant activity .....	2
Autologous and allogeneic transplants .....	2
Stem cell source for autologous transplants .....	3
Stem cell source for allogeneic transplants.....	3
Indications for autologous transplant .....	4
Indications for allogeneic transplant.....	4
Donor source for allogeneic transplants.....	5
Transplant activity by age group .....	5
<b>Registry activity 2022.....</b>	<b>6</b>
Haematopoietic cell transplant and CAR-T activity summary .....	6
Transplant activity by state and country.....	7
Transplant activity 2022 by state / country and hospital type.....	8
Haematopoietic cell transplants by type.....	9
Outpatient procedures.....	9
<b>Transplant and recipient characteristics .....</b>	<b>10</b>
Transplant recipients by age group.....	10
Stem cell source by donor type.....	11
Conditioning intensity for allogeneic transplants by age group .....	11
HLA compatibility for allogeneic transplants .....	12
<b>Indication for transplant .....</b>	<b>13</b>
Recipients aged 0-15 by transplant type.....	13
Recipients aged 0-15: transplant indications .....	14
Acute leukaemia by disease stage, all ages (allogeneic transplants).....	14
Recipients aged 16+: autologous transplants .....	15
Recipients aged 16+: allogeneic transplants .....	16
<b>Unrelated donor transplants .....</b>	<b>17</b>
Stem cell source - recipients aged 0-15.....	17
Stem cell source - recipients aged 16+ .....	17
Stem cell source for unrelated transplants - Australia and New Zealand .....	18
Donor country for Australian unrelated donor transplants.....	19
Australian peripheral blood and marrow transplants.....	19
Australian cord blood transplants.....	19
Donor country - marrow and peripheral blood.....	20
Donor country - cord blood.....	20
Adverse events in the first 100 days .....	21
Performance status 1 year post transplant (Lansky/Karnofsky).....	21

<b>Outcomes in the first year post transplant.....</b>	<b>22</b>
Recipients aged 0-15 .....	22
Neutrophil engraftment 2022 – matched sibling donor .....	22
Neutrophil engraftment 2022 – unrelated donor .....	22
Platelet engraftment 2022 – matched sibling donor.....	23
Platelet engraftment 2022 – unrelated donor.....	23
Acute GVHD 2022 all grades – matched sibling donor.....	24
Acute GVHD 2022 all grades – unrelated donor.....	24
Acute GVHD 2022 grade II and above – matched sibling donor .....	25
Acute GVHD 2022 grade II and above – unrelated donor .....	25
Chronic GVHD 2001-21 – matched sibling donor.....	26
Chronic GVHD 2001-21 – other related donor.....	26
Chronic GVHD 2001-21 – unrelated donor.....	27
One year survival 2001-2021 .....	27
Recipients aged 16+ .....	28
Neutrophil engraftment 2022– matched sibling donor .....	28
Neutrophil engraftment 2022 – unrelated donor .....	28
Platelet engraftment 2022 – matched sibling donor.....	29
Platelet engraftment 2022 – unrelated donor.....	29
Neutrophil engraftment 2022 - autologous for lymphoma (BEAM conditioning) .....	30
Neutrophil engraftment 2022 – autologous for myeloma (Melphalan conditioning) ..	30
Platelet engraftment 2022– autologous for lymphoma (BEAM conditioning).....	31
Platelet engraftment 2022 – autologous for myeloma (Melphalan conditioning) .....	31
Acute GVHD 2022 all grades - matched sibling donor .....	32
Acute GVHD 2022 all grades – unrelated donor.....	32
Acute GVHD 2022 grade II and above - matched sibling donor .....	33
Acute GVHD 2022 grade II and above – unrelated donor .....	33
Chronic GVHD 2001-21 – matched sibling donor.....	34
Chronic GVHD 2001-21 – other related donor.....	34
Chronic GVHD 2001-21 – unrelated donor.....	35
One year survival 2001-2021 .....	35
<b>Ten-year survival - first transplants 2001-2021 .....</b>	<b>36</b>
Recipients aged 0-15 .....	36
Acute lymphoblastic leukaemia - HLA identical sibling donor .....	36
Acute lymphoblastic leukaemia - unrelated donor .....	36
Acute lymphoblastic leukaemia - unrelated cord vs other related donor .....	37
Acute myeloid leukaemia - HLA identical sibling donor .....	37
Immune deficiencies .....	38
Aplastic anaemia.....	38
Neuroblastoma.....	39
Medulloblastoma .....	39

Recipients aged 16+ .....	40
Acute myeloid leukaemia - HLA identical sibling donor .....	40
Acute myeloid leukaemia - unrelated donor.....	40
Acute myeloid leukaemia - unrelated cord vs other related donor .....	41
Acute lymphoblastic leukaemia - HLA identical sibling donor .....	41
Acute lymphoblastic leukaemia - unrelated donor .....	42
Acute lymphoblastic leukaemia - unrelated cord vs other related donor .....	42
Chronic myeloid leukaemia - HLA identical sibling donor .....	43
Chronic myeloid leukaemia - unrelated donor .....	43
Myelodysplasia - HLA-identical sibling donor .....	44
Myelodysplasia - unrelated donor .....	44
Myeloma by ISS score – autologous 5 year survival .....	45
Myeloma – first transplants .....	45
Hodgkin lymphoma – autologous.....	46
Non-Hodgkin lymphoma – autologous.....	46
Non-Hodgkin lymphoma – allogeneic .....	47
Non-Hodgkin lymphoma – allogeneic .....	47
Primary amyloidosis .....	48
Testicular cancer.....	48
Aplastic anaemia.....	49
Ewing sarcoma - adult and paediatric autologous .....	49
<b>Transplant related mortality.....</b>	<b>50</b>
100 day and 1 year TRM 2017-2021 .....	50
TRM trends: recipients aged 0-15.....	50
TRM trends: recipients aged 16+ .....	51
<b>Cause of death post transplant.....</b>	<b>52</b>
Recipients aged 0-15 .....	52
Primary cause of death post autologous transplant.....	52
Primary cause of death post allogeneic transplant - first year .....	53
Contributing causes of TRM in the first year by allogeneic donor type .....	53
Contributing causes of TRM at 100 days and 1 year post allogeneic transplant .....	54
Primary cause of death post allogeneic transplant - second year .....	54
Recipients aged 16+ .....	55
Primary cause of death post autologous transplant.....	55
Contributing causes of TRM at 100 days and 1 year post autologous transplant.....	55
Primary cause of death post allogeneic transplant - first year .....	56
Contributing causes of TRM by allogeneic donor type .....	56
Contributing causes of TRM at 100 days and 1 year post allogeneic transplant .....	57
Primary cause of death post allogeneic transplant - second year .....	57
<b>Contributing centres .....</b>	<b>58</b>
Australia .....	58
New Zealand .....	58
<b>Recent publications .....</b>	<b>59</b>